Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

Published:2007-08-16 Issue:12 Volume:22 Page:1832-1841
ISSN:0884-0431
Container-title:Journal of Bone and Mineral Research
language:en
Short-container-title:J Bone Miner Res

Author:

Lewiecki E Michael,Miller Paul D,McClung Michael R,Cohen Stanley B,Bolognese Michael A,Liu Yu,Wang Andrea,Siddhanti Suresh,Fitzpatrick Lorraine A

Publisher

Wiley

Subject

Orthopedics and Sports Medicine,Endocrinology, Diabetes and Metabolism

Reference25 articles.

1. Epidemiology of osteoporotic fractures;Johnell;Osteoporos Int,2005

2. Quality of life, morbidity, and mortality after low trauma hip fracture in men;Pande;Ann Rheum Dis,2006

3. Hip fracture: Risk factors and outcomes;Wehren;Curr Osteoporos Rep,2003

4. An estimate of the worldwide prevalence, mortality and disability associated with hip fracture;Johnell;Osteoporos Int,2004

5. Osteoclast differentiation and activation;Boyle;Nature,2003

Cited by 275 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of denosumab and teriparatide versus oral bisphosphonates to treat postmenopausal osteoporosis: a systematic review and meta-analysis;Frontiers in Endocrinology;2024-09-02

2. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials;Osteoporosis International;2024-05-11

3. Current perspectives on the multiple roles of osteoclasts: Mechanisms of osteoclast–osteoblast communication and potential clinical implications;eLife;2024-04-09

4. Evaluation of Bone Density Changes Before and After One Year of Denosumab (Prolia) Administration in Osteoporosis Patients;Annals of Military and Health Sciences Research;2024-03-12

5. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males;Expert Opinion on Biological Therapy;2024-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3